GLORIA PHARMA.(SZ:002437) 智通财经网·2026-01-20 09:36Core Viewpoint - Yuheng Pharmaceutical (002437.SZ) expects a significant increase in net profit for the fiscal year 2025, projecting a range of CNY 350 million to CNY 420 million, representing a year-on-year growth of 50.37% to 80.44% [1] Financial Performance - The company anticipates a net profit attributable to shareholders of CNY 350 million to CNY 420 million, with a year-on-year increase of 50.37% to 80.44% [1] - The net profit after deducting non-recurring gains and losses is projected to be between CNY 185 million and CNY 220 million, reflecting a growth of 0.92% to 20.02% year-on-year [1] Product Performance - Key products such as injectable multivitamins, potassium chloride sustained-release tablets, and other medications have shown substantial and steady sales growth [1] - Additional products contributing to revenue growth include sitagliptin and metformin sustained-release tablets, flurbiprofen ester injection, and injectable papaverine hydrochloride [1]